
Dr. Abbey Discusses How Vorolanib Could Shift the Treatment Approach for Diabetic Macular Edema in New Retinal Physician Article
Texas Retina’s Ashkan M. Abbey, MD, served as a principal site investigator for the Phase II VERONA clinical trial evaluating the efficacy and safety of the vorolanib intravitreal insert (EYP-1901) in diabetic
read more
Welcome Rocío Díaz, MD!
Texas Retina is pleased to welcome board-certified ophthalmologist and retina specialist Rocío Díaz, MD, to our practice on June 4, 2025. Serving patients in our Wichita Falls office, she will provide care
read more
Our Offices Will Close for Memorial Day
All Texas Retina offices will be closed on Monday, May 26, in observance of Memorial Day. We remember and honor all who gave their lives in service to our country.
read more
Can Ozempic Affect Your Eyes or Vision?
Initially approved by the U.S. Food and Drug Administration (FDA) to help control blood sugar and treat type 2 diabetes, semaglutide (brand names Ozempic, Wegovy and Rybelsus) has also emerged as a
read more
Texas Retina Associates Participating in Phase III Clinical Trial for Choroidal Melanoma
Under the leadership of principal investigator Timothy Fuller, MD, Texas Retina is participating in the Phase III AU-011 clinical trial (CoMpass) for treatment of small choroidal (ocular) melanoma. Together with Aura Biosciences,
read more
Dr. Wang Presented Study Results of New Wet AMD Treatment Approach at the ARVO 2025 Meeting
On May 9, 2025, Texas Retina’s Robert C. Wang, MD, presented “Top Line Results from ODYSSEY: A Phase IIb Study of Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-related Macular Degeneration” at
read more
May is Ocular Melanoma Awareness Month
Ocular (uveal) melanoma is a rare but dangerous disease, and only a small number of doctors in the United States treat it. At Texas Retina, we have been caring for ocular melanoma
read more